2005 performance highlights

82.6p earnings per share, 18% CER growth in 2005

£4.7bn free cash flow increase of 26% over 2004

95 NCEs in clinical development at the end of 2005 -70% increase over 2001

25 vaccines in clinical development at the end of 2005 with five major vaccine launches anticipated in the next five years

35% market share by value of Avandia/Avandament in the USA - increase of 6 percentage points over 2004

27% market share by value of Seretide/Advair in Europe - increase of 2 percentage points over 2004

&pound;380m - value of community investment in 2005 equivalent to 5.6% of profit before tax

136m albendazole tablets donated to help eliminate lymphatic filiariasis